RedHill Biopharma Ltd. (RDHL) Given a $33.00 Price Target at HC Wainwright
RedHill Biopharma Ltd. (NASDAQ:RDHL) has been assigned a $33.00 price target by equities researchers at HC Wainwright in a research report issued on Friday. The brokerage currently has a a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 139.30% from the stock’s current price.
Several other equities analysts have also recently commented on RDHL. FBR & Co reissued a “buy” rating on shares of RedHill Biopharma in a research report on Friday, September 9th. Zacks Investment Research raised shares of RedHill Biopharma from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, June 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. RedHill Biopharma currently has a consensus rating of “Buy” and an average price target of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) remained flat at $13.79 during midday trading on Friday. The company had a trading volume of 36,547 shares. The company has a 50 day moving average of $14.75 and a 200 day moving average of $12.75. RedHill Biopharma has a 1-year low of $8.10 and a 1-year high of $16.54. The company’s market cap is $175.60 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/redhill-biopharma-ltd-rdhl-given-a-33-00-price-target-at-hc-wainwright.html
RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.52. On average, analysts anticipate that RedHill Biopharma will post ($2.06) EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. Van ECK Associates Corp boosted its stake in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of RedHill Biopharma during the second quarter worth about $142,000. Royal Bank of Canada boosted its stake in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares during the last quarter. Finally, Ingalls & Snyder LLC acquired a new stake in shares of RedHill Biopharma during the second quarter worth about $451,000. 15.30% of the stock is currently owned by institutional investors.
RedHill Biopharma Company Profile
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.